our towards disease, untapped , trial great GRANITE in we're momentum has conference randomized self-amplifying clinical Thanks, for infectious significant the exciting And cancer This established vaccine data. really George. or for PCV called for of is realizing time joining which strides us our first mRNA. And afternoon, making with call. personalized quarter XXXX for good everybody. potential Thanks Gritstone, is been program a driving
will of GRANITE with financials then I'll we announced a begin corporate to come Celia the back closing of review today. study including and share the I'll recent expansion and call present clinical today's remarks. developments, the
Okay, let's right in. dive
this you This which Phase the the study from with a Microsatellite share we to newly , study. Phase today important I'll currently enrollment to regarding at I'm very you achieving in enrolling most Cancer. with patients Colorectal an refer to GRANITE Metastatic our shared patients update is rapid tell initial of diagnosed in we're So Stable morning, enrollment MSS-CRC. pace X part that X/X update target of close delighted And a to XX and is
the the patients. the neoantigen SLATE and term to that We data But portion also to order value our of must be expand second X/X this, our to course, term is strategic a fiddle to of we'll high X funds to future. from play shifting announced PCV key Phase XXX study of part program SLATE. trial this near expected off-the-shelf we've near maximize planned deliver as decision Phase made not GRANITE total the And in we opportunity. is of potential randomized thus the do
be could years, approach strong with power that patients immunotherapy capable unlocking of me tumors. uniquely for the our cold over of OUR heard you've speak belief Now of PCV the immunologically
provocative further adenocarcinoma at data positive Our Phase the in PCV therapeutic evidence provided time published and a Phase summer, data, further of hot Vinod and just yesterday of from context in of this Balachandran data in Nature ACR immunology tumors, approach. Kettering supporting adjuvant Medicine in supporting cancer. X/X data GRANITE patients advanced And April, the clinical adjuvant case included strong Nature, provided with the Moderna’s recent immunologically immunologically that melanoma. from pancreatic the in hypothesis. data therapy cancer published Moderna’s in potentially Memorial clinical ductal last support team cold his In Sloan then the cold some context XV in PCV in pancreatic presented of
Phase with tumor in that PCV potentially Our against being recognized I immunotherapy, benefit further if treat cold. metastatic all think for all MSS-CRC together application enormous GRANITE MSS-CRC. this And and randomized the delivers X notoriously based difficult study comes is first both that a hot potentially how encompasses it's and trial is cold and opportunity current the data, tumors to is with supporting widely neoantigen GRANITE solid new our to deliver
expand the Now, are we why reasons there study. Phase several to elected X
them. detail me Let
number which X a Phase study effect will of size, patients provide treatment large size. a better sample inform in of optimal Firstly, will an estimate turn
down is you remind response, on endpoint a PFS survival Phase survival molecular X drill is for or ctDNA including component efficacy OS. study X/X. to secondary with the that Phase designed free the progression or primary to as endpoints response, current or overall and point, So And the
of Phase Phase will determined be Phase effect authorities from X Phase estimate it X PFS, easier statistically is data. we endpoints regulatory observed it endpoint of Phase primary The Powering with efficacy then with the Phase components the a traditional of X done the Now X anticipate and to data, discussing size the likely our for based time interaction X the Since regulators, power in X study to separate. Phase but as X appropriately. X moving into are such the be data to Phase event treatment OS. is first endpoint greater the is and The using be precision XXXX X. on to half
trend is up. XXX strong XXXX. randomized that behind consenting expect completing for anticipate of and these third in to XXth, very continue half already future. momentum were patients, all as enrollment foreseeable full quarter the initially XX approximately the enthusiastically We been we've we Secondly, and of the May this screening of XXXX, randomized has And of and the of in strong enrollment of gone the sites XX XXXX, enrollment study number subjects planned
to clinical high worth the need. and desperately needed. Colorectal years. death are to needed, States diagnosed the patients cancer people Median is momentum this sadly United we expected XXX,XXX this is cause and aim arises CRC over in leading be are unmet second year therapeutics disease around from for deliver Better Now is innovation in metastatic survival reflecting with alone. the of cancer with on, both. two part And
Thirdly, CDA tip basic benefit. our neoantigen is programs. that potent of for to spear vaccine GRANITE the delivering The is the drive patients strong neoantigens will idea a in tumor responses that solid drives clinical T cell many
data identification rate do to survival to anti-tumor an administered T mutations the experience platform, and immune strong neural Leveraging that mount patients seeks forms effective we've approximately network well which to true most cells, will patients as trafficking with GRANITE killing cells clinical Now evidenced cell and with neoantigen of our of EDGE, that tumor T into stimulate epitope as subset that. the molecular tumors response response overall predict by accurately XX% molecular responses you neoantigens are that exactly without. our DNA responses aware, show And observed. data extended versus that those our further their those tumor show published
antigens and each but that a patient. always which off-the-shelf be temporarily it time behind delivers PCV GRANITE antigens than identify will program, into can to combined single shared tumor is antigens It a work more rapidly each that an patient, out multiple tumor approach specific development. takes shared We're However, to high quality vaccine in take SLATE, relevant off-the-shelf specific to building time delivers cost approach. our and
likely SLATE leads follow. GRANITE where So will
However, showing term delivers our controlled priority. efficacy GRANITE randomized highest the is in trial a near
that response an anything ctDNA GRANITE making that Now size, circulating as rapidly surrogate progressive radiology errors susceptible we is of antigen stable assess and sense this in molecular or because bigger. to tumor us makes or based before appear like radiology or costing tumor to issue what's cell mislabeling in destruction are fact, immunotherapy. ctDNA obviously remain in we response on immune solid of or the Gritstone This to proliferate, at over system T respectively, a molecular is they can of where potentially have tumor from Tumor the to may we value cognate lesions. into i.e. decrease in your reflected by biomarker of ctDNA efficacy as assessment time. complex when disease DNA be stable. patient's in disease newly meet tumor in the I'd on those label our over war referred makes on reduction likely key increase at dynamics draw aim lesions efficacy the move oncology, the drive but ctDNA, going in actually It particular lesions, tools attention light lesions stable their with a to a emerging of to as cells for superior biomarker early studies, shown and
originally molecular carefully data waited cancer done And study We in in endpoint primary PhaseX/X reduction our define X predict before. cancer. clinical Now, GRANITE we've mature is endpoint. to data that response ctDNA Phase molecular study. defined to patients in allow advanced our a this no a this survival remind the driven one's the response XX% portion And in to to overall is best expected for the colorectal manner you, us study for of as as from for powered
specific So we've responses tumor ever had inhibition. novo with this in T one's patients No No cold to build generated before. checkpoint cell combined the strong one's de framework neoantigen ourselves.
X/X done. answer. and answer So what for the definition And Phase We've We've had there driven trial. controlled endpoint question, X to off-the-shelf overall survival? no data now we're best exactly the deploying efficacy in data surrogate randomized find generated a the we've in Phase to what's is to establish a that's
a accelerated in endpoint of have emerging dependent GRANITE or possibility X. serve We're cancer there enough I've Once such X XXXX the X, and the trial, to pivotal immunotherapy into a but efficacy a would tumors. gained, by trial, using in a is for its to approval. pivotal PCV as by momentum extend has Phase potential are to molecular as like be anticipate as a major as the support we in will to surrogate And efficacy that, very advance but response on endpoint that been seek it's demonstrated we'll as traditional benefits proceed PFS, Phase not cold used already accrued OS excited we noted, the we We it. Phase
update you and enrollment data complete, the we of first XXXX. further preliminary quarter to on once forward will in We look sharing
associated goods enable of XXrd European more of potentially from neutralizing once prolonged vaccinations. cost where continue non-amplifying immunogenicity the of centered this regardless clinical from now antibody over CORAL disease, In CEPI a advantages infectious studies demonstrating across becoming at expression new as replication and with benefit. flow antigen from candidates for of over the setting Diseases, that need and at in to mRNA mRNA the RNA samRNA also translating These known our dose, a cell be appears to persist ECCMID. our on appears six response, as the responses called multiple fraction BOOST of antibody presented differentiation X booster move clearer. similar the Phase mRNA at stage samRNA or month we vaccines Microbiology months, least durable presentations frequent April six subject Clinical a And generation program samRNA neutralizing first the populations. vaccines in our data antibody SARS-CoV-X. of to offering driven the for neutralizing called year, self-amplifying by robust into data Infectious let's The reducing Copenhagen the vaccine potential Congress and mRNA demonstrated of samRNA to Now And is of ongoing
over to work of long the both platform Phase and the seeing persistence generation our CEPI tolerable that and look the COVID-XX. with at to reports. of rapidly against forward emerging we neutralizing immune in and meaningful other and prior our We X induction vaccine diseases, platform studies levels highly to is And note proof naive including field. against data promising demonstrate collaborators vaccines infectious broad, subject XXX presentation, next subjects, numbers variant in immunogenic in flexible SARS-CoV-X full the Of responses potential in is versus reported call six viruses. a potentially samRNA for a months high samRNA term increase we're our as for continuing antibody important
to in this data illustrating flexibility designs, It additional different data efficient fall. accommodate to White need that by is B that solutions formats. share CORAL to pursuit recent the is from T the are the there and immunogen going durability signals will the BARDA generation relate Cell clear breadth both and and our of enhanced is still expect the platform We actions of And epitopes program next and COVID-XX encouraging wayside. against these cell protection not to House of the for
vaccines our PCV forward of potentially SARS-CoV-X Outside identify to transformative develop and our and continues. looking programs, efforts
immunotherapy in Retroviruses curative influenza, treatments at a Our new continued this and partnership HIV to Conference vaccine study, for and study with presented results remains on Phase our progress a Infections ongoing against promising in projects the January. preclinical were preclinical and non-human respiratory primates develop virus, and a from Gilead in Human within based active viruses program a well. vaccine Opportunistic multiple Papilloma to against And combination X
to XXXX. it for color Celia? I'll over our now of financial more Celia, provide who turn results quarter the first on will
